QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
How do we assess the value of medicines – and what´s next for HTA in Finland?
Quantify Research‘s Finnish team is excited to take part in Pharma Academy’s event on Health Technology Assessment (HTA) on May 21st, 2025!
This event will explore how we assess the therapeutic and economic value of treatments, how real-world data supports decision-making, and how HTA is evolving in both national and international contexts.
🔍 Key discussions points:
🟢 HTA’s role in access and reimbursement decisions
🟢 Using real-world […]
How Can Finland Stay At the Forefront of Registry-Based Research?
Quantify Research Finland has submitted its statement on the proposed amendment to the Secondary Use Act, which addresses the data permit process, international collaboration, and anonymization regulation.
As a leading Nordic real-world evidence (RWE) provider, we’re well-placed to evaluate how Finland’s registry-based research legislation can be improved to ensure global leadership.
Our stance is clear: efficient, secure, and fair processes are vital for high-quality research […]
ISPOR Day 2 wrap-up…
⚡ Another dynamic day at ISPORAnnual in Montreal! From insightful posters to creative strategy sessions, our teams at Quantify and IGES Institut stayed busy and inspired.
🤝 The poster sessions delivered again today, sparking vibrant discussions in addition to the many conversations with clients, collaborators, and old industry friends throughout the day.
🧠 One of the highlights? Continued collaboration and creative brainstorming between the Quantify and IGES teams. We’re energised by […]
ISPOR Day 1 comes to a close…
⚡Quantify closed out an exciting first day at ISPORAnnual in Montreal today. Highlights included our workshop Bridging the Evidence Gap: Integrating Real-World Data With Randomized Controlled Trials where our own Emilie Toresson Grip and Kirk Geale, PhD discussed external control arms (ECAs) and transportability analyses respectively. We were happy to see a few hundred interested listeners turn out for this session […]